Based on recent developments, it appears that pharmaceutical giant Pfizer has reached settlements worth over 10,000 cases related to cancer risks associated with the discontinued heartburn medication Zantac. These agreements pertain to lawsuits filed in US state courts, although they do not entirely resolve all Zantac-related claims against the company. The specific financial terms of these settlements have not yet been disclosed.
In 2020, the US Food and Drug Administration requested that pharmaceutical companies withdraw Zantac and its generic counterparts from the market due to the discovery of carcinogenic substances, namely NDMA, in sample batches of the medication. This led to a wave of legal action being initiated against Pfizer, GlaxoSmithKline (GSK), Sanofi, and Boehringer Ingelheim in both federal and state courtrooms respectively.
At this time, Pfizer has declined to offer any comments regarding the settlements.
Leave a Reply